Forte Biosciences is a clinical-stage biopharmaceutical company whose lead product candidate is FB102. FB102 is a proprietary molecule with potentially broad autoimmune and autoimmune-related applications. In June 2025, we announced positive data from the FB102 celiac disease study. A Phase 2 celiac disease has been initiated with data expected in 2026. Additionally, a vitiligo trial has commenced enrollment with topline data expected in 1H26 and an alopecia areata trial is initiating in 2H25 with topline data expected in 2026.